Display options
Cite
Kamusheva M, Vassileva M, Savova A, et al. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries. Front Public Health. 2018;6:61doi: 10.3389/fpubh.2018.00061.
Kamusheva, M., Vassileva, M., Savova, A., Manova, M., & Petrova, G. (2018). An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries. Frontiers in public health, 661. https://doi.org/10.3389/fpubh.2018.00061
Kamusheva, Maria, et al. "An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries." Frontiers in public health vol. 6 (2018): 61. doi: https://doi.org/10.3389/fpubh.2018.00061
Kamusheva M, Vassileva M, Savova A, Manova M, Petrova G. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries. Front Public Health. 2018 Mar 05;6:61. doi: 10.3389/fpubh.2018.00061. eCollection 2018. PMID: 29556491; PMCID: PMC5845108.
Copy Download .nbib Format: NLM
Share it on

Front Public Health. 2018 Mar 05;6:61. doi: 10.3389/fpubh.2018.00061. eCollection 2018.

An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries.

Frontiers in public health

Maria Kamusheva, Mariya Vassileva, Alexandra Savova, Manoela Manova, Guenka Petrova

Affiliations

  1. Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria.
  2. National Council on Prices and Reimbursement, Sofia, Bulgaria.

PMID: 29556491 PMCID: PMC5845108 DOI: 10.3389/fpubh.2018.00061

Abstract

BACKGROUND: Policy makers face a lot of challenges in the process of drug reimbursement decision-making, especially in the context of entering the market of more and more innovative medicinal products (MPs). The aim of the current study is to make an overview of the reimbursement system development and to evaluate the access of innovative medicines, which have entered the EU-market in the period 2015-2017, in Bulgaria as reference example for middle-income European country.

METHODS: A literature and a legislative systematic review regarding the Bulgarian reimbursement system as well as a defining the number of available innovative reimbursed MPs in 2017 in Bulgaria was made.

RESULTS: The reimbursement legislation in Bulgaria is quite unstable due to constant changes, which have been made, especially in the recent years. Despite this fact, the reimbursement process in Bulgaria is in accordance with the Transparency Directive. Bulgarian patients have a relatively delayed access to innovative medicines as only 5% of centrally authorized MPs in 2017 are available in the positive drug list (PDL), 16% of all in 2016 and 18%-in 2015. This could be explained by the long procedure for their appraisal in Bulgaria: the first step is issuing an opinion by the HTA Committee, followed by negotiation of discounts between the marketing authorization holder and the National Health Insurance Fund and making a final decision by the National Council on Prices and Reimbursement (NCPR) for the inclusion into the PDL.

CONCLUSION: Optimization of the procedure for issuing reimbursement status for innovative MPs is needed, such as improvements in the process of conducting HTA reports and their appraisal, incorporation of adequate systems for following the effectiveness and safety of MPs in the real-world conditions, value-based pricing implementation, and increasing the financial control over the health insurance system.

Keywords: Bulgaria; access; affordability; innovative medicines; low and middle-income Balkan countries; positive drug list; reimbursement

References

  1. Int J Technol Assess Health Care. 2017 Jan;33(3):390-395 - PubMed
  2. Int J Technol Assess Health Care. 2017 Jan;33(3):376-383 - PubMed
  3. Int J Technol Assess Health Care. 2017 Jan;33(3):345-349 - PubMed
  4. Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):537-46 - PubMed
  5. Int J Technol Assess Health Care. 2017 Jan;33(3):365-370 - PubMed
  6. Biotechnol Biotechnol Equip. 2014 Nov 2;28(6):1181-1189 - PubMed
  7. Health Policy. 2017 Mar 31;:null - PubMed
  8. Front Pharmacol. 2017 Jun 08;8:288 - PubMed
  9. J Med Econ. 2017 Oct;20(10 ):1013-1017 - PubMed
  10. Eur J Cancer. 2017 Apr;75:313-322 - PubMed
  11. Front Public Health. 2015 Apr 22;3:64 - PubMed
  12. Front Public Health. 2015 Apr 23;3:65 - PubMed
  13. Health Syst Transit. 2016 Aug;18(4):1-170 - PubMed
  14. Health Syst Transit. 2016 Oct;18(5):1-122 - PubMed
  15. J Mark Access Health Policy. 2017 Sep 25;5(1):1381544 - PubMed
  16. Front Public Health. 2015 Jun 01;3:152 - PubMed
  17. Front Public Health. 2017 Nov 08;5:295 - PubMed
  18. PLoS One. 2017 Dec 28;12 (12 ):e0190147 - PubMed

Publication Types